Natural Good Things Achieves Major Success with Taiwanese Artist Halo Mavis, Records 250,000 Live Commerce Sales
SEOUL, South Korea, Jan. 26, 2026 /PRNewswire/ -- Women's wellness inner-care brand Natural Good Things (NGT) is making significant strides in the global market through a strategic partnership with Taiwanese artist and mega influencer Halo Mavis. NGT announced that it achieved cumulative sales of approximately 250,000 units through four live commerce collaborations conducted over the past year with top Taiwanese...
Ascletis Announces First Participants Dosed in a 13-week U.S. Phase II Study with ASC30, an Oral Small Molecule GLP-1R Agonist for the Treatment of Diabetes
-Topline data from the Phase II study for the treatment of diabetes are expected in the third quarter of 2026. -ASC30 demonstrated placebo-adjusted weight loss of up to 7.7% in a recently completed 13-week U.S. Phase II study in participants with obesity or overweight, with better gastrointestinal tolerability. No hepatic safety signal was observed. HONG KONG, Jan. 26, 2026 /PRNewswire/...
Landmark FDA Move: First Quality Control Protocol for Mesenchymal Stromal Cells (MSCs) Sets New Therapeutic Standard
TIANJIN, China, Jan. 26, 2026 /PRNewswire/ -- In a landmark move for the cell therapy industry, a Device Master File (DMF) describing the first dedicated quality control standard for Mesenchymal Stromal Cells (MSCs) was accepted by the U.S. Food and Drug Administration (FDA). The agency's Master File acknowledgement letter, issued on January 9, 2026, incorporates the "Tasly 3P Characterization of...
Insilico Medicine Receives IND Approval from FDA for ISM8969, an AI-empowered Potential Best-in-class NLRP3 Inhibitor
Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) paves the way for ISM8969 clinical study in the United States. The Phase I clinical trial aims to evaluate safety, tolerability, and pharmacokinetics profiles. ISM8969 is a novel oral therapeutic candidate developed through Insilico's Pharma.AI, with best-in-class potential, unique brain penetrant traits, and favorable druggability...
Ozelle Brings AI-Powered, Scenario-Ready Diagnostics to WHX Labs Dubai 2026
DUBAI, UAE, Jan. 23, 2026 /PRNewswire/ -- Ozelle, a global innovator in intelligent diagnostics, will showcase its next-generation solution at WHX Labs Dubai 2026 (Feb 10–13, Booth S1.D58). Under the theme "AI × CBM: The Next-Generation of Complete Blood Morphology," Ozelle will highlight how diagnostic testing can evolve beyond standalone analyzers toward intelligent, scenario-ready solutions designed to bridge the...
Study demonstrates effectiveness and economic value of Myriad™ in trauma and acute care surgery.
AUCKLAND, New Zealand, Jan. 23, 2026 /PRNewswire/ -- Aroa Biosurgery Limited is pleased to announce that the latest publication from its ongoing prospective study, the Myriad Augmented Soft Tissue Reconstruction Registry (MASTRR), has been published in the Journal of Trauma and Injury. MASTRR is the largest ongoing prospective, multicenter observational study to collect patient data from the use of...
Insilico Medicine Launches Science MMAI Gym to Transform Frontier LLMs into Pharmaceutical-Grade Scientific Engines
New "AI GYM for Science" dramatically boosts the biological and chemical intelligence of any causal or frontier LLM Up to 10x performance gains on key drug discovery benchmarks compared to LLMs that miss the mark on ~75–95% of tasks Advances Insilico's vision of Pharmaceutical Superintelligence (PSI) CAMBRIDGE, Mass., Jan. 22, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", HKEX: 3696),...
Mindray Unveils Three-Pillar Growth Strategy at 2026 J.P. Morgan Healthcare Conference, Paving the Way for Next Decade of Global Healthcare Innovation
SHENZHEN, China, Jan. 22, 2026 /PRNewswire/ -- May Li, Board Secretary of Mindray Medical (300760.SZ), delivered a keynote speech at the 44th J.P. Morgan Healthcare Conference (JPM Conference) on January 15, 2026, outlining the company's strategic vision for the next decade centered on three core pillars: Globalization, Recurring Business Expansion, and Intelli-Digitalization. The speech also showcased significant progress in Mindray's...
Mabwell Announces First-Patient Dosed in Clinical Trial of Novel CDH17-Targeting ADC 7MW4911 in the U.S.
SHANGHAI, Jan. 22, 2026 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that the first patient has been dosed in a clinical trial in the U.S. of its independently developed novel CDH17-targeting antibody-drug conjugate (ADC) (R&D code: 7MW4911) for the treatment of advanced colorectal cancer and other advanced gastrointestinal tumors. The Phase...
Jin Medical Announces the Official Commencement Date of Chuzhou Facility
CHANGZHOU, China, Jan. 22, 2026 /PRNewswire/ -- Jin Medical International Ltd. (NASDAQ: ZJYL) ("Jin Medical", and together with all its subsidiaries, the "Company"), a NASDAQ-listed leading provider of rehabilitation medical equipment in China, announced today that its wholly-owned subsidiary, Zhongjin Medical Equipment (Anhui) Co., Ltd., has made significant progress in the final construction of its manufacturing facility in...
